METHODOLOGY: A systematic search was conducted on October 1, 2022, on PubMed, Scopus, Google, and the British Broadcasting Corporation (BBC) News's official website to identify COVID-19 apps available in Vietnam. The apps were evaluated through user reviews and content analysis of their specific features and drawbacks.
RESULTS: Thirty Vietnam-based COVID-19 mobile apps were identified on the Apple and Google Play Store. Their functions were recorded and analyzed using a dedicated tool for appraising mobile applications. Although useful, many specific COVID-19 features were dispersed and duplicated between the apps. The most comprehensive apps still lack important functionalities, such as vaccination information. The most serious user concerns were privacy breaches during data recording and storage, technical issues, and non-user-friendly interfaces.
CONCLUSIONS: The panorama of current COVID-19 apps in Vietnam is complex and includes many apps. Their overlap in features and functions could create a dispersion of mobile users that could undermine the apps' usefulness and effectiveness in combating the pandemic in Vietnam. An app that integrates the most useful features and addresses the main issues could facilitate user experience and usage uptake.
METHODS: Data were collected for infants born before 32 weeks gestation and/or weighing less than 1.8 kg treated for CMV disease with GCV or valGCV between 2016 and 2023.
RESULTS: Twenty-four infants (58% males and 48% Asian ethnicity) with a median gestation of 31 weeks [interquartile range (IQR): 26.6-36.1], median weight of 950 g (IQR: 470-1692) and median age of 45 days (IQR: 6-84) at initiation of treatment were included. Seventeen infants were treated for symptomatic postnatal CMV and 7 for symptomatic congenital CMV. Most infants receiving GCV had 6 mg/kg twice daily dosing and most receiving valGCV had 16 mg/kg twice daily dosing. Fourteen infants had drug concentrations measured with combined geometric mean minimum blood plasma concentration (Cmin) of 2.44 mg/L and maximum blood plasma concentration of 7.98 mg/L for doses of 6 mg/kg GCV and 16 mg/kg valGCV, which is higher compared with term infants. The estimated area under the curve at 12 hours (AUC0-12h) was 54.34 mg × h/L, which doubled the value for term infants in a previous study. Notably, AUC0-12h had an inverse relationship with gestational age and weight. Infants with lower gestation and higher Cmin showed a higher tendency for more than 1 adverse effect.
CONCLUSIONS: GCV and valGCV use among preterm and very low birthweight infants with CMV disease resulted in a higher incidence of adverse events, increased AUC0-12h and elevated Cmin compared with term infants. Further pharmacokinetic studies are necessary to determine the ideal dosage in this population.
METHODS: A familial case of pituitary disease was investigated. We also examined 36 pituitary organogenesis genes in 134 individuals with pituitary tumours using a targeted next-generation sequencing panel, identifying and characterising variants with a population allele frequency C, p.(D129A). In our broader study, we identified an additional individual with the FGFR1 D129A variant and demonstrated enrichment compared to a control population derived from the Genome Aggregation Database (gnomAD). We also observed 66 rare germline variants in pituitary organogenesis genes amongst 54/134 individuals (40%). However, compared to control data, the study cohort exhibited no enrichment for other rare variants in FGFR1, FGF-related genes, or other pituitary embryogenesis genes.
CONCLUSION: Our results suggest that the FGFR1 D129A variant may be associated with pituitary tumorigenesis but the role of other pituitary embryogenesis genes remains unclear. Additional independent cohorts and functional studies are required.
METHODS: Data from the 2022 national health survey were utilized. Face-to-face interviews were conducted using a standard questionnaire on contraceptive use among the eligible WR who provided written consent. Unmet needs refer to fecund WR who are not using any contraceptive method but wish to either limit childbearing (cease having children) or space pregnancies (delay their next birth).
RESULTS: Out of 1,987 eligible WR, 1,877 respondents were interviewed, resulting in an 86.6% response rate. This study focused on 1,236 WR who were currently married or in a union and fecund. The prevalence of unmet family planning needs was 26.7% (95% CI: 22.6, 31.3) with 20.7% (95% CI: 17.1, 24.8) attributed to unmet needs for limiting and 6.0% (95% CI: 3.9, 9.3) for spacing. Unmet family planning needs were associated with WR who resided in Peninsular Malaysia (adjusted Odds Ratio (aOR) = 2.42, 95% CI: 1.36, 4.30), those employed in the private sector (aOR = 2.07, 95% CI: 1.16, 3.66), and those aged 35 years and above (aOR = 1.70, 95% CI: 1.08, 2.66).
CONCLUSIONS: Unmet family planning needs are prevalent in Malaysia and associated with specific WR groups. An in-depth study should follow these findings to identify barriers in accessing family planning services, which are currently available.
SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12070-024-05259-6.